medigraphic.com

2015, Número S2

<< Anterior Siguiente >>

Rev Mex Anest 2015; 38 (S2)


Manejo de la hemorragia crítica en insuficiencia hepática

Díaz-Carrillo MA, Carrillo-Esper R

Idioma: Español
Referencias bibliográficas: 29
Paginas: 397-401
Archivo PDF: 219.86 Kb.


RESUMEN

Los pacientes con insuficiencia hepática con frecuencia muestran profundas alteraciones en su sistema hemostático. Mientras que las pruebas de laboratorio de rutina sugieren que estas alteraciones hemostáticas dan como resultado diátesis hemorrágica, la evidencia científica demostrada tanto en estudios clínicos y de laboratorio sugieren que la situación es más compleja. El paciente promedio con insuficiencia hepática puede estar en equilibrio hemostático a pesar de las alteraciones en las pruebas de coagulación, ya que los factores a favor y en contra de la hemostasia se ven afectados; los factores antihemostáticos no son valorables con las pruebas de coagulación de rutina. Esta condición puede plantear dilemas diagnósticos y terapéuticos para los médicos. Con la alta tasa de complicaciones hemorrágicas en pacientes con cirrosis, examinamos los distintos procoagulantes disponibles para su uso en esta población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol. 2010;53:362-371.

  2. Lisman T, Caldwell SH, Leebeek FW, Porte RJ. Is chronic liver disease associated with a bleeding diathesis? J Thromb Haemost. 2006;4:2059-2060.

  3. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol. 2007;46:727-733.

  4. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250-258.

  5. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039-1046.

  6. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345:669-681.

  7. Violi F, Leo R, Basili S, Ferro D, Cordova C, Balsano F. Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica. 1994;79:61-65.

  8. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992;15:672-676.

  9. Tacke F, Fiedler K, Trautwein C. A simple clinical score predicts high risk for upper gastrointestinal hemorrhages from varices in patients with chronic liver disease. Scand J Gastroenterol. 2007;42:374-382.

  10. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33:41-48.

  11. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27:1207-1212.

  12. Vivas S, Rodríguez M, Palacio MA, Linares A, Alonso JL, Rodrigo L. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci. 2001;46:2752-2757.

  13. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thromboelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut. 1998;43:267-271.

  14. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood. 1990;75:1753-1762.

  15. Iber FL, Shamszad M, Miller PA, Jacob R. Vitamin K deficiency in chronic alcoholic males. Alcohol Clin Exp Res. 1986;10:679-681.

  16. Saja MF, Abdo AA, Sanai FM, Shaikh SA, Gader AG. The coagulopathy of liver disease: does vitamin K help? Blood Coagul Fibrinolysis. 2013;24:10-17.

  17. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med. 1981;305:242-248.

  18. Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42:365-370.

  19. O’Shaughnessy DF, Atterbury C, Bolton-Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.

  20. Shah NL, Intagliata NM, Northup PG, Argo CK, Caldwell SH. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol. 2014;11:675-682.

  21. Boks AL, Brommer EJ, Schalm SW, van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology. 1986;6:79-86.

  22. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol. 2008;15:473-480.

  23. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138:534-540.

  24. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193.

  25. Bosch J, Thabut D, Bendtsen F, D’Amico G, Albillos A, González-Abraldes J, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130.

  26. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47:1604-1614.

  27. Violi F, Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost. 2013;39:426-433.

  28. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149-154.

  29. Arshad F, Ickx B, van Beem RT, Polak W, Grüne F, Nevens F, et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surg. 2013;13:22.




2020     |     www.medigraphic.com